The role of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in the management of diabetic complications

Drugs

Volumn 62, Issue 14, 2002, Pages 2007-2012

  Podar, Toomas ^a   Tuomilehto, Jaakko ^b,c  

^a TARTU UNIVERSITY CLINICS   (Estonia)

^b UNIVERSITY OF HELSINKI   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LISINOPRIL; PLACEBO; RAMIPRIL;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG EFFECT; HUMAN; KIDNEY FUNCTION; MICROVASCULATURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR DISEASE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; RECEPTORS, ANGIOTENSIN;

EID: 0036402540     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262140-00001     Document Type: Review

References (38)

1. NHBPE Program. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994; 23: 145-60
2. Joint National Committee on Prevention, Detection, Evaluation, et al. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-46
3. Sowers JR. Comorbidity of hypertension and diabetes: The fosinopril versus amlodipine cardiovascular events trial (FACET). Am J Cardiol 1998; 82: 15R-9R
4. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-61
5. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13
6. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-20
7. Lindholm L, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: Results from the Swedish trial in old patients with hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000; 18: 1671-5
8. Tuomilehto J, Rastenyte D, Birkenhänger WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677-84
9. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9
10. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: Double blind randomised trial. BMJ 2002; 324: 699
11. Hansson L, Lindholm L, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6
12. Niskanen L, Hedner T, Hansson L, et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ace inhibitor compared with a diuretic/[beta]-blocker-based treatment regimen: A subanalysis of the captopril prevention project. Diabetes Care 2001; 12: 2091-6
13. Chantrel F, Moulin B, Hannedouche T. Blood pressure, diabetes and diabetic nephropathy. Diabetes Metab 2000; 26 Suppl. 4: 37-44
14. Parving HH, Andersen AR, Smidt UM, et al. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;1:1175-9
15. Mathiesen ER, Hommel E, Giese J, et al. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991; 303: 81-7
16. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-92
17. Lewis E, Hunsicker L, Bain R, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-62
18. Mogensen CE, Neldam S, Tikkanen I, et al. for the CALM study group. Randomised controlled trial of dual blockade of reninangiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-4
19. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52
20. Estacio RO, Jeffers BW, Gifford N, et al. Effect of blood pressure control on diabetic microvascular complications on patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 Suppl. 2: B54-64
21. Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086-97
22. Ravid M, Brosh D, Levi Z, et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: A randomized, controlled trial. Ann Intern Med 1998; 128: 982-8
23. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999; 131: 660-7
24. Leehey D, Singh A, Alavi N, et al. Role of angiotensin II in diabetic nephropathy. Kidney Int 2000; 58 Suppl. 77: S93-8
25. Lewis E, Hunsicker L, Clarke W, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60
26. Parving H, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8
27. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 1004-10
28. Larsen M, Hommel E, Parving HH, et al. Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy. Graefes Arch Clin Exp Ophthalmol 1990; 228: 505-9
29. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351: 28-31
30. Caldwell P, Seegal B, Hsu K, et al. Angiotensin converting enzyme, vascular endothelial localization. Science 1976; 191: 1050-1
31. Williams B. Angiotensin II, VEGF, and diabetic retinopathy. Lancet 1998; 351: 837-8
32. Cameron NE, Cotter MA. Robertson S. Rapid reversal of a motor nerve conduction deficit in streptozotocin-diabetic rats by the angiotensin converting enzyme inhibitor lisinopril. Acta Diabetol 1993; 30: 46-8
33. Cameron NE, Cotter MA, Robertson S. Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia 1992; 35: 12-8
34. Reja A, Tesfaye S, Harris ND, et al. Is ACE inhibition with lisinopril helpful in diabetic neuropathy? Diabet Med 1995; 12: 307-9
35. Kontopoulos AG, Athyros VG, Didangelos TP, et al. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 1997; 20: 355-61
36. Malik RA, Williamson S, Abbott C, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: Randomised double-blind controlled trial. Lancet 1998; 352: 1978-81
37. Hoogwerf BJ, Young JB. The HOPE study: Ramipril lowered cardiovascular risk, but vitamin E did not. Cleve Clin J Med 2000; 67: 287-93
38. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003